Novo Nordisk A/S (NVO)vsPepsiCo Inc (PEP)
NVO
Novo Nordisk A/S
$46.07
+0.59%
HEALTHCARE · Cap: $202.85B
PEP
PepsiCo Inc
$154.62
-1.07%
CONSUMER DEFENSIVE · Cap: $213.64B
Smart Verdict
WallStSmart Research — data-driven comparison
Novo Nordisk A/S generates 243% more annual revenue ($327.80B vs $95.45B). NVO leads profitability with a 37.2% profit margin vs 9.2%. PEP appears more attractively valued with a PEG of 1.68. NVO earns a higher WallStSmart Score of 74/100 (B).
NVO
Strong Buy74
out of 100
Grade: B
PEP
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for NVO.
Margin of Safety
-1.0%
Fair Value
$154.81
Current Price
$154.62
$0.19 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Attractively priced relative to earnings
Every $100 of equity generates 71 in profit
Keeps 37 of every $100 in revenue as profit
Strong operational efficiency at 61.6%
Earnings expanding 67.1% YoY
Mega-cap, among the largest globally
Every $100 of equity generates 44 in profit
Earnings expanding 27.8% YoY
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Expensive relative to growth rate
Trading at 9.9x book value
Weak financial health signals
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : NVO
The strongest argument for NVO centers on Market Cap, P/E Ratio, Return on Equity. Profitability is solid with margins at 37.2% and operating margin at 61.6%. Revenue growth of 24.0% demonstrates continued momentum.
Bull Case : PEP
The strongest argument for PEP centers on Market Cap, Return on Equity, EPS Growth.
Bear Case : NVO
The primary concerns for NVO are Piotroski F-Score, PEG Ratio.
Bear Case : PEP
The primary concerns for PEP are PEG Ratio, Price/Book, Piotroski F-Score.
Key Dynamics to Monitor
NVO profiles as a growth stock while PEP is a value play — different risk/reward profiles.
PEP carries more volatility with a beta of 0.39 — expect wider price swings.
NVO is growing revenue faster at 24.0% — sustainability is the question.
NVO generates stronger free cash flow (12.0B), providing more financial flexibility.
Bottom Line
NVO scores higher overall (74/100 vs 63/100), backed by strong 37.2% margins and 24.0% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novo Nordisk A/S
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.
PepsiCo Inc
CONSUMER DEFENSIVE · BEVERAGES - NON-ALCOHOLIC · USA
PepsiCo, Inc. is an American based multinational food, snack, and beverage corporation headquartered in Harrison, New York, in the hamlet of Purchase. PepsiCo's business encompasses all aspects of the food and beverage market. It oversees the manufacturing, distribution, and marketing of its products.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?